These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9366279)

  • 1. Treatment of heart failure with fosinopril: an angiotensin converting enzyme inhibitor with a dual and compensatory route of excretion.
    Mancia G; Giannattasio C; Grassi G
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):236S-241S. PubMed ID: 9366279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of congestive heart failure: experience with fosinopril.
    Blumenthal M
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):289S-298S. PubMed ID: 9366286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure.
    Davis R; Coukell A; McTavish D
    Drugs; 1997 Jul; 54(1):103-16. PubMed ID: 9211084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure.
    Galatius S; Wroblewski H; Sørensen V; Haunsø S; Nørgaard T; Kastrup J
    J Card Fail; 1999 Mar; 5(1):17-24. PubMed ID: 10194656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosinopril. Clinical pharmacokinetics and clinical potential.
    Shionoiri H; Naruse M; Minamisawa K; Ueda S; Himeno H; Hiroto S; Takasaki I
    Clin Pharmacokinet; 1997 Jun; 32(6):460-80. PubMed ID: 9195116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.
    Kostis JB; Garland WT; Delaney C; Norton J; Liao WC
    Clin Pharmacol Ther; 1995 Dec; 58(6):660-5. PubMed ID: 8529331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurohormonal activation and the response to converting enzyme inhibitors in congestive heart failure.
    Kubo SH
    Circulation; 1990 Feb; 81(2 Suppl):III107-14. PubMed ID: 2137052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radial, carotid and aortic distensibility in congestive heart failure: effects of high-dose angiotensin-converting enzyme inhibitor or low-dose association with angiotensin type 1 receptor blockade.
    Giannattasio C; Achilli F; Failla M; Capra A; Vincenzi A; Valagussa F; Mancia G
    J Am Coll Cardiol; 2002 Apr; 39(8):1275-82. PubMed ID: 11955844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fosinopril in the treatment of cardiorenal syndrome in chronic cardiac failure].
    Tereshchenko SN; Zhirov IV
    Ter Arkh; 2009; 81(5):84-8. PubMed ID: 19537594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of angiotensin-converting enzyme inhibitors in congestive heart failure].
    Takeuchi K; Takeda T
    Nihon Rinsho; 1993 May; 51(5):1287-92. PubMed ID: 8331796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACE inhibitors: review of four new agents.
    Binder SB
    Am Fam Physician; 1993 Oct; 48(5):851-7. PubMed ID: 8213415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Galvao M
    Heart Lung; 1990 Sep; 19(5 Pt 1):505-11. PubMed ID: 2211159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal functional alterations induced by angiotensin-converting enzyme inhibitors in heart failure.
    Munger MA
    Ann Pharmacother; 1993 Feb; 27(2):205-10. PubMed ID: 8439700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension.
    Wagstaff AJ; Davis R; McTavish D
    Drugs; 1996 May; 51(5):777-91. PubMed ID: 8861547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.
    O'Grady P; Yee KF; Lins R; Mangold B
    Br J Clin Pharmacol; 1999 Sep; 48(3):375-81. PubMed ID: 10510149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril.
    Galatius-Jensen S; Wroblewski H; Emmeluth C; Bie P; Haunsø S; Kastrup J
    Cardiovasc Res; 1996 Dec; 32(6):1148-54. PubMed ID: 9015418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
    Červenka L; Melenovský V; Husková Z; Škaroupková P; Nishiyama A; Sadowski J
    Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):795-807. PubMed ID: 25969338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurohumoral mechanisms in cardiocirculatory decompensation].
    Grassi G; Mancia G
    Ann Ital Med Int; 1994 Oct; 9 Suppl():61S-67S. PubMed ID: 7857760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of chronic heart failure with angiotensin-converting enzyme inhibitors].
    Schofer J
    Dtsch Med Wochenschr; 1988 Oct; 113(43):1684-9. PubMed ID: 2846252
    [No Abstract]   [Full Text] [Related]  

  • 20. The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group.
    Sharma S; Deitchman D; Eni JS; Gelperin K; Ilgenfritz JP; Blumenthal M
    Am J Ther; 1999 Jul; 6(4):181-9. PubMed ID: 11329095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.